[4] Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for US$900 million.

[1][5] In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company[6][7] increasing the Baxalta share price over 16%.

Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36%, compared to the company's stock price on August 3.

[8] This deal would create the largest global biotech company focused solely on rare diseases.

[9] Subsequently, Shire was acquired by Takeda Pharmaceutical Company for $62 billion in January 2019.